Media releases
- December
- 21-Dec-2012 Novartis drug Exjade® approved by European Commission for iron overload in patients with non-transfusion-dependent thalassemia »
- 15-Dec-2012 Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder »
- 11-Dec-2012 Two-year data show new Novartis drug Jakavi® significantly reduced myelofibrosis disease burden and suggest overall survival advantage »
- 10-Dec-2012 Novartis long-term Phase III data show Ph+ CML patients on Tasigna® achieved significantly deeper molecular response versus Glivec® »
- 04-Dec-2012 Novartis Foundation symposium discusses psychosocial support to help vulnerable children achieve mental health and wellbeing for a better future in sub-Saharan Africa »
- November
- 28-Nov-2012 Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS »
- 20-Nov-2012 Novartis receives FDA approval for Flucelvax®, the first cell-culture vaccine in US to help protect against seasonal influenza »
- 16-Nov-2012 Novartis drug Exjade® recommended by CHMP for EU approval to treat patients with non-transfusion-dependent thalassemia syndromes »
- 16-Nov-2012 Novartis receives positive CHMP opinion for Bexsero®, a groundbreaking vaccine to help prevent devastating MenB infections, the leading cause of meningitis in Europe »
- 12-Nov-2012 Novartis new two-year data with Certican® shows positive outcomes at 24 months in largest liver transplant trial to date »
- 11-Nov-2012 Novartis data show ACZ885 delivered rapid and strong symptom relief while reducing frequency of attacks in two periodic fever syndromes »
- 09-Nov-2012 Italian authorities lift precautionary hold on Novartis seasonal influenza vaccines »
- 09-Nov-2012 Novartis announces update to company's Board of Directors to take effect in February 2013 »
- 08-Nov-2012 Novartis future growth prospects secured by industry-leading pipeline, with more than 139 projects with 73 new compounds »
- 07-Nov-2012 Novartis drug Signifor® recommended by FDA advisory committee for approval to treat patients with Cushing's disease »
- 07-Nov-2012 Novartis Phase III study shows RLX030 improved symptoms and reduced deaths by one-third in patients with acute heart failure »
- 05-Nov-2012 Novartis drug Votubia® approved in the EU as first medication to treat patients with non-cancerous kidney tumors associated with TSC »
- October
- 31-Oct-2012 Health Canada and Swissmedic lift precautionary holds on Novartis seasonal influenza vaccines »
- 31-Oct-2012 Novartis to start construction of new biotechnology facility in Singapore with an investment of over USD 500 million »
- 25-Oct-2012 Recently launched products support Novartis sales in third quarter, offsetting patent expiry; Pharmaceuticals well-positioned with further pipeline progress »
- 25-Oct-2012 Novartis confident in safety and efficacy of its seasonal influenza vaccines produced in Italy »
- 12-Oct-2012 New analysis indicates that Novartis drug Gilenya shows significant early effect on reducing brain volume loss at 6 months »
- 01-Oct-2012 Novartis receives European Commission approval for once-daily Seebri® Breezhaler® as maintenance COPD treatment in the EU »
- September
- 27-Sep-2012 Novartis data show AIN457 significantly reduced signs and symptoms in patients with hard-to-treat moderate-to-severe plaque psoriasis »
- 24-Sep-2012 Results from Novartis Phase III study show that RLX030 reduced deaths in patients with acute heart failure »
- 21-Sep-2012 Novartis announces two CHMP positive opinions for new indications of Galvus® and Eucreas® combined with other diabetes treatments »
- 21-Sep-2012 Novartis drug Votubia® recommended by CHMP for EU approval to treat patients with non-cancerous kidney tumors associated with TSC »
- 05-Sep-2012 New data for Novartis drug Lucentis® confirms long-term efficacy and safety profile and benefits of individualized treatment »
- 03-Sep-2012 Novartis data at ERS shows efficacy of once-daily COPD portfolio versus comparators, further establishes dual-bronchodilator QVA149 »
- August
- 30-Aug-2012 Novartis QVA149 Phase III study meets primary endpoint in reducing exacerbations in COPD patients, filing in EU and Japan by end of year »
- 29-Aug-2012 Novartis International BioCamp Highlights Global R&D Reach to Meet Patient Needs in Emerging Markets »
- 28-Aug-2012 Novartis drug Jakavi® first medication to receive European Commission approval to treat patients with myelofibrosis »
- 26-Aug-2012 New Novartis Phase II data show LCZ696 may provide clinical benefits in patients with a difficult-to-treat form of heart failure »
- 15-Aug-2012 Phase III results published in NEJM show ocriplasmin could be first pharmacological eye treatment for vitreomacular adhesion patients »
- 06-Aug-2012 Novartis and University of Pennsylvania form broad-based R&D alliance to advance novel T-cell immunotherapies to treat cancer »
- July
- 30-Jul-2012 Novartis drug Afinitor® approved by European Commission to treat patients with the most common form of advanced breast cancer »
- 20-Jul-2012 Novartis gains FDA approval for Afinitor® in advanced breast cancer marking a significant milestone for women battling this disease »
- 19-Jul-2012 Novartis second quarter results enhance future growth prospects with eight significant regulatory milestones; on track to deliver 2012 outlook »
- June
- 22-Jun-2012 Novartis receives positive CHMP opinion for once-daily Seebri® Breezhaler® to treat COPD patients in the EU »
- 22-Jun-2012 CHMP recommends Novartis drug Afinitor® for EU approval marking major milestone in the treatment of advanced breast cancer »
- 11-Jun-2012 Novartis drug Gilenya® shows long-term efficacy and safety according to new data from extension of phase III head-to-head study »
- 06-Jun-2012 Novartis Phase III study showed 62% of patients with most severe form of childhood arthritis were symptom-free with ACZ885 treatment »
- May
- 31-May-2012 Novartis showcases ongoing research at ASCO to help patients fight various cancers, including updated data in advanced breast cancer »
- 17-May-2012 Novartis NVA237 Phase III data showed rapid, sustained improvement in lung function and symptom relief over one year in COPD patients »
- 10-May-2012 New data among 200 Lucentis® abstracts at ARVO show low number of injections with Novartis drug required to achieve and maintain vision gains over 3 years in AMD and DME patients »
- 07-May-2012 Novartis drug pasireotide LAR shows superior efficacy compared to Sandostatin® LAR® in Phase III trial of patients with acromegaly »
- 02-May-2012 Sandoz to acquire Fougera Pharmaceuticals, becoming the number one generic dermatology medicines company globally and in the US »
- 01-May-2012 Recent publicly-funded CATT trial highlights serious safety concerns around unlicensed ocular bevacizumab use versus Lucentis »
- April
- 26-Apr-2012 Novartis drug Afinitor® approved by FDA as first medication to treat patients with non-cancerous kidney tumors associated with TSC »
- 26-Apr-2012 More than 25,000 Novartis associates worldwide to volunteer for local causes in Community Partnership Day »
- 25-Apr-2012 Novartis drug Signifor® approved in the EU as the first medication to treat patients with Cushing's disease »
- 24-Apr-2012 Pharmaceuticals and Alcon performed strongly in the first quarter; overall Group results impacted by expected challenges »
- 20-Apr-2012 Novartis drug Jakavi(TM) recommended by CHMP for EU approval to treat patients with the life-threatening blood cancer myelofibrosis »
- 20-Apr-2012 Novartis updates US label on Gilenya® following discussions with the FDA »
- 20-Apr-2012 Novartis confirms positive benefit-risk profile of Gilenya® following CHMP review and label update recommendation »
- 19-Apr-2012 Novartis announces Aliskiren will continue to be available to appropriate patients, as FDA interim assessment is concluded; product information updated »
- 19-Apr-2012 New extension study data with Novartis drug Gilenya® shows patients successfully treated for up to 7 years in relapsing MS »
- 02-Apr-2012 Novartis QVA149 Phase III COPD studies meet primary endpoints »
- March
- 28-Mar-2012 Novartis launches the Cancer Cell Line Encyclopedia (CCLE) to catalogue world's cancer cell lines »
- 27-Mar-2012 Study in JAMA reports significant survival benefit in certain GIST patients taking Novartis drug Glivec® for three years after surgery »
- 16-Mar-2012 Alcon gains exclusive ex-US rights for ocriplasmin, potential first pharmacological treatment for symptomatic vitreomacular adhesion »
- 07-Mar-2012 Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushing's disease patients in Phase III study »
- February
- 29-Feb-2012 Brian McNamara Named Division Head, Novartis OTC »
- 29-Feb-2012 Two Phase III studies of Novartis drug INC424 published in NEJM show significant clinical benefit for patients with myelofibrosis »
- 27-Feb-2012 European Commission approves new label for Novartis drug Glivec® extending adjuvant therapy to three years for certain GIST patients »
- 23-Feb-2012 Shareholders approve all proposed resolutions of Novartis Board of Directors »
- 17-Feb-2012 Novartis to revise product information in the European Union for high blood pressure drug Rasilez® following assessment by CHMP »
- 13-Feb-2012 FDA requests additional data on Novartis quadrivalent meningococcal conjugate vaccine, Menveo®, for expanded use in infants and toddlers »
- 07-Feb-2012 Pivotal study published in JAMA confirms potential of Novartis candidate vaccine Bexsero® to help protect infants against devastating meningococcal serogroup B disease »
- 01-Feb-2012 FDA approves Novartis drug Glivec® label recommending extending treatment to three years for certain GIST patients after surgery »
- January
- 30-Jan-2012 Novartis extends commitment to help achieve final elimination of leprosy »
- 25-Jan-2012 Novartis delivers strong underlying financial performance in 2011, expects 2012 sales to be in line with 2011 »
- 20-Jan-2012 CHMP recommends EU approval to update Novartis drug Glivec® label to include three year treatment for GIST patients after surgery »
- 20-Jan-2012 Novartis drug Signifor® recommended by CHMP for EU approval to treat patients with Cushing's disease »
- 19-Jan-2012 Sandoz initiates two more Phase III biosimilar trials, reinforcing long-term global leadership commitment »
- 18-Jan-2012 Novartis receives approval for Lucentis® and launches Galvus® in China, two innovative therapies that support public health goals »
- 13-Jan-2012 Novartis to restructure US business to strengthen competitive position in light of loss of Diovan® patent and announces charge for Rasilez®/Tekturna® »
- 08-Jan-2012 Novartis Consumer Health Inc. voluntarily recalls certain over-the-counter products in the US while Novartis Group strengthens quality standards across all manufacturing sites »
The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.
